Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23295353 | 0.75 | LMNA (0.39) | LMNAKDM4E | |
| SCHEMBL23000888 | 0.71 | LMNA (0.37) | LMNAKDM4E | |
| SCHEMBL24127548 | 0.70 | LMNA (0.39) | LMNA | |
| SCHEMBL8060090 | 0.69 | — | — | |
| SCHEMBL23894127 | 0.68 | LMNA (0.38) | LMNA | |
| SCHEMBL2442544 | 0.68 | LMNA (0.38) | LMNA | |
| SCHEMBL23295530 | 0.67 | MEN1 (0.38) | LMNA | |
| SCHEMBL25041772 | 0.65 | LMNA (0.35) | LMNAKDM4E | |
| SCHEMBL25039080 | 0.65 | LMNA (0.35) | LMNAKDM4E | |
| SCHEMBL23894132 | 0.64 | LMNA (0.34) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4284360-A1 | AMINOTHIOLESTER COMPOUND OR DERIVATIVE THEREOF FOR USE AS AN IMMUNOMODULATORY AGENT | Advanced Biodesign (FR) | 2023-12-06 | — | — | EP | claimed |
| US-20230149378-A1 | Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use for the treatment of cancer | ADVANCED BIODESIGN (FR) | 2023-05-18 | — | — | US | claimed |
| EP-3362056-B1 | AMINOTHIOLESTER COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, FOR USE IN THE TREATMENT OF CANCER | ADVANCED BIODESIGN (FR) | 2021-02-24 | — | — | EP | claimed |
| EP-3362094-B1 | COMBINATION COMPRISING AN AMINOTHIOLESTER COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A COMPOUND ABLE TO INCREASE THE H2O2 LEVEL IN CANCER CELLS OF A SUBJECT | ADVANCED BIODESIGN (FR) | 2021-02-17 | — | — | EP | claimed |
| US-10406125-B2 | Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the H2O2 level in cancer cells of a subject | ADVANCED BIODESIGN (FR) | 2019-09-10 | — | — | US | claimed |
| US-20180303773-A1 | COMBINATION COMPRISING AN AMINOTHIOLESTER COMPOUND OR A HARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A COMPOUND ABLE TO INCREASE THE 2O2 LEVEL IN CANCER CELLS OF A SUBJECT | ADVANCED BIODESIGN (FR) | 2018-10-25 | — | — | US | claimed |
| US-20180296548-A1 | AMINOTHIOLESTER COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, FOR USE IN THE TREATMENT OF CANCER | ADVANCEDC BIODESIGN (FR) | 2018-10-18 | — | — | US | claimed |
| EP-3362056-A1 | AMINOTHIOLESTER COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, FOR USE IN THE TREATMENT OF CANCER | Advanced Biodesign (FR) | 2018-08-22 | — | — | EP | claimed |
| EP-3362094-A1 | COMBINATION COMPRISING AN AMINOTHIOLESTER COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A COMPOUND ABLE TO INCREASE THE H2O2 LEVEL IN CANCER CELLS OF A SUBJECT | Advanced Biodesign (FR) | 2018-08-22 | — | — | EP | claimed |
| WO-2017064241-A1 | COMBINATION COMPRISING AN AMINOTHIOLESTER COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A COMPOUND ABLE TO INCREASE THE H2O2 LEVEL IN CANCER CELLS OF A SUBJECT | ADVANCED BIODESIGN (FR) | 2017-04-20 | — | — | WO | claimed |
| WO-2017064247-A1 | AMINOTHIOLESTER COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, FOR USE IN THE TREATMENT OF CANCER | ADVANCED BIODESIGN (FR) | 2017-04-20 | — | — | WO | claimed |
| US-8026231-B2 | Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof | CNRS (FR) | 2011-09-27 | — | — | US | claimed |
| US-7078402-B2 | Aminothiol ester compounds, pharmaceutical and cosmetics compositions containing same and uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2006-07-18 | — | — | US | claimed |
| EP-1296946-B1 | AMINOTHIOLESTER COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME AND USES THEREOF | GALDERMA RES & DEV (FR) | 2004-04-21 | — | — | EP | claimed |
| US-20030181443-A1 | Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof | ADVANCED BIODESIGN (FR) | 2003-09-25 | — | — | US | claimed |
| EP-1296946-A1 | AMINOTHIOLESTER COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME AND USES THEREOF | Galderma Research & Development, S.N.C. (FR) | 2003-04-02 | — | — | EP | claimed |
| WO-2001092220-A1 | AMINOTHIOLESTER COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME AND USES THEREOF | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2001-12-06 | — | — | WO | claimed |
| EP-4284360-A1 | AMINOTHIOLESTER COMPOUND OR DERIVATIVE THEREOF FOR USE AS AN IMMUNOMODULATORY AGENT | Advanced Biodesign (FR) | 2023-12-06 | — | — | EP | disclosed |
| EP-1296946-B1 | AMINOTHIOLESTER COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME AND USES THEREOF | GALDERMA RES & DEV (FR) | 2004-04-21 | — | — | EP | disclosed |
| US-20030181443-A1 | Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof | ADVANCED BIODESIGN (FR) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296548-A1 | AMINOTHIOLESTER COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, FOR USE IN THE TREATMENT OF CANCER | SHMT2, CTH, MGMT | LMNA 4874/4885KDM4E 319/4885 |
| US-20180303773-A1 | COMBINATION COMPRISING AN AMINOTHIOLESTER COMPOUND OR A HARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A COMPOUND ABLE TO INCREASE THE 2O2 LEVEL IN CANCER CELLS OF A SUBJECT | BHMT2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SHMT2 | LMNA 4786/4885KDM4E 769/4885 |
| US-10406125-B2 | Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the H2O2 level in cancer cells of a subject | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CTH, MGMT | LMNA 4876/4885KDM4E 416/4885 |
| US-20030181443-A1 | Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof | AADAT, ALDH7A1, TYR | LMNA 2556/4885KDM4E 2839/4885 |
| US-20230149378-A1 | Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use for the treatment of cancer | SHMT2, CTH, MGMT | LMNA 4874/4885KDM4E 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.